[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7P8w3Dl_-nN6uD5xE10Vux70VXeblmFxF6lLyVf8cWM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"Vastra Gotaland Region",[4],266,false,120,10,1265608,43,203,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Breast Cancer",16,{"name":18,"count":19},"Rheumatoid Arthritis",9,{"name":21,"count":22},"Primary Health Care",6,{"name":24,"count":22},"Depression",{"name":26,"count":22},"Obesity",{"name":28,"count":29},"Physical Activity",5,{"name":31,"count":29},"Melanoma",{"name":33,"count":29},"Diabetes Mellitus, Type 1",[35,40,45,50,55,60,65,70,75,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06169072","Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients","2024-07-01","Superparamagnetic Iron Oxide",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05903937","Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases","2024-12-31","Autologous Tumor Infiltrating Lymphocytes",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03560310","Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome","2025-03-13","Ticagrelor 90mg twice daily and ASA 75-100 mg daily",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT02936505","Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","2025-10-30","Cyclosporine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05716607","Treatment Study in Patients Treated With Both Insulin & Hydrocortisone","2025-12","OD dual-release Hydrocortisone",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT04125563","Influence on Cough and Airway Symptoms by Oral Capsaicin","2025-12-30","Capsicum Oleoresin",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04101877","The Sahlgrenska Anti-VEGF Study","2026-10","Bevacizumab",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05132179","Treating Diabetic Foot Ulcers, Comparing Two Topical Antimicrobial Agents, Dakin´s and Prontosan","2026-12-31","Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution",{"nctId":76,"briefTitle":77,"date":73,"intervention":78},"NCT03685890","Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion","Nivolumab",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT07012863","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting","2027-06-30","Dry plasma",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,133,159,177,195,222,249,273,291,317,335,353,381,399,426,444,468,493,521,539,579,610,646,677,707,725,748,766,789,807,848,874,900,927,945,963,981,999,1019,1047,1070,1088,1113,1142,1166,1190,1208,1233,1262,1289,1315,1342,1360,1395,1419,1437,1464,1489,1517,1535,1563,1581,1599,1624,1649,1667,1692,1710,1738,1756,1774,1792,1810,1837,1863,1885,1911,1937,1955,1980,2006,2034,2052,2070,2088,2114,2132,2159,2177,2202,2220,2246,2270,2300],{"intervention":93,"totalTrials":94,"cells":95},"Adenosine",2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":115,"NA":131},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":58,"start":111,"enrollment":98,"conditions":112,"interventions":114},"NCT05014061","Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction","WITHDRAWN",[88],"2025-06","2023-01-01",[113],"Myocardial Ischemia",[93],{"trials":116,"activeCount":130,"soonestReadout":122},[117],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT04666454","BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.","RECRUITING",[89],"2028-12","2020-12-14",1000,[126],"Takotsubo Syndrome",[93,128,129],"Dipyridamole 200 mg","Apixaban 5 mg Oral",1,{"trials":132,"activeCount":98},[],{"intervention":134,"totalTrials":130,"cells":135},"Bisoprolol Oral",{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":157},{"trials":137,"activeCount":98},[],{"trials":139,"activeCount":98},[],{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":98},[],{"trials":145,"activeCount":130,"soonestReadout":150},[146],{"nctId":147,"briefTitle":148,"status":120,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":8,"conditions":152,"interventions":154},"NCT06562582","STunning in Acute Myocardial Infarction - BAS",[89],"2027-12-31","2025-01-06",[153],"Myocardial Infarct",[134,155,156],"Ramipril Oral Product","Dapagliflozin Oral Product",{"trials":158,"activeCount":98},[],{"intervention":155,"totalTrials":130,"cells":160},{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":169,"NA":175},{"trials":162,"activeCount":98},[],{"trials":164,"activeCount":98},[],{"trials":166,"activeCount":98},[],{"trials":168,"activeCount":98},[],{"trials":170,"activeCount":130,"soonestReadout":150},[171],{"nctId":147,"briefTitle":148,"status":120,"phases":172,"primaryCompletion":150,"completion":150,"start":151,"enrollment":8,"conditions":173,"interventions":174},[89],[153],[134,155,156],{"trials":176,"activeCount":98},[],{"intervention":156,"totalTrials":130,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":193},{"trials":180,"activeCount":98},[],{"trials":182,"activeCount":98},[],{"trials":184,"activeCount":98},[],{"trials":186,"activeCount":98},[],{"trials":188,"activeCount":130,"soonestReadout":150},[189],{"nctId":147,"briefTitle":148,"status":120,"phases":190,"primaryCompletion":150,"completion":150,"start":151,"enrollment":8,"conditions":191,"interventions":192},[89],[153],[134,155,156],{"trials":194,"activeCount":98},[],{"intervention":196,"totalTrials":130,"cells":197},"Capecitabine + Radiotherapy",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":220},{"trials":199,"activeCount":98},[],{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":98},[],{"trials":207,"activeCount":130,"soonestReadout":213},[208],{"nctId":209,"briefTitle":210,"status":211,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT07483060","Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer","NOT_YET_RECRUITING",[89],"2028-12-31","2031-12","2026-03-12",90,[218],"Rectal Cancer",[196],{"trials":221,"activeCount":98},[],{"intervention":83,"totalTrials":130,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":232,"NA":247},{"trials":225,"activeCount":98},[],{"trials":227,"activeCount":98},[],{"trials":229,"activeCount":98},[],{"trials":231,"activeCount":98},[],{"trials":233,"activeCount":130,"soonestReadout":82},[234],{"nctId":80,"briefTitle":81,"status":211,"phases":235,"primaryCompletion":82,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":246},[89],"2027-09-30","2026-01-01",650,[240,241,242,243,244,245],"Bleeding","Aortic Rupture","Gastrointestinal Hemorrhage","Obstetric Bleeding","Blunt Injury","Penetrating Injury",[83],{"trials":248,"activeCount":98},[],{"intervention":49,"totalTrials":130,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":271},{"trials":252,"activeCount":98},[],{"trials":254,"activeCount":98},[],{"trials":256,"activeCount":98},[],{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":130,"soonestReadout":48},[261],{"nctId":46,"briefTitle":47,"status":262,"phases":263,"primaryCompletion":48,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"ACTIVE_NOT_RECRUITING",[89],"2035-02-15","2018-06-29",2201,[268],"Acute Coronary Syndrome",[49,270],"ASA 75-160 mg daily",{"trials":272,"activeCount":98},[],{"intervention":270,"totalTrials":130,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":289},{"trials":276,"activeCount":98},[],{"trials":278,"activeCount":98},[],{"trials":280,"activeCount":98},[],{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":130,"soonestReadout":48},[285],{"nctId":46,"briefTitle":47,"status":262,"phases":286,"primaryCompletion":48,"completion":264,"start":265,"enrollment":266,"conditions":287,"interventions":288},[89],[268],[49,270],{"trials":290,"activeCount":98},[],{"intervention":292,"totalTrials":130,"cells":293},"Optilume",{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":315},{"trials":295,"activeCount":98},[],{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":130,"soonestReadout":308},[304],{"nctId":305,"briefTitle":306,"status":120,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT06795074","Risk of Recurrent Urethral Stricture After Treatment With Paclitaxel-Coated Dilatation Balloon (Optilume) Compared With Non-coated Dilatation Balloon",[89],"2029-02","2031-02","2026-01-16",230,[313],"Urethral Stricture",[292],{"trials":316,"activeCount":98},[],{"intervention":128,"totalTrials":130,"cells":318},{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":327,"NA":333},{"trials":320,"activeCount":98},[],{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":130,"soonestReadout":122},[329],{"nctId":118,"briefTitle":119,"status":120,"phases":330,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":331,"interventions":332},[89],[126],[93,128,129],{"trials":334,"activeCount":98},[],{"intervention":129,"totalTrials":130,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":351},{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":130,"soonestReadout":122},[347],{"nctId":118,"briefTitle":119,"status":120,"phases":348,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":349,"interventions":350},[89],[126],[93,128,129],{"trials":352,"activeCount":98},[],{"intervention":354,"totalTrials":130,"cells":355},"busulfan, cyclophosphamide and melphalan, BuCyMel",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":377,"NA":379},{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":130,"soonestReadout":368},[364],{"nctId":365,"briefTitle":366,"status":120,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":375},"NCT05477589","Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML",[88],"2029-12-31","2031-12-31","2022-06-07",170,[373,374],"Acute Myeloid Leukemia (AML) in Remission","Stem Cell Transplantation",[354,376],"clofarabine, fludarabine and busulfan, CloFluBu",{"trials":378,"activeCount":98},[],{"trials":380,"activeCount":98},[],{"intervention":376,"totalTrials":130,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":395,"NA":397},{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":130,"soonestReadout":368},[391],{"nctId":365,"briefTitle":366,"status":120,"phases":392,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":393,"interventions":394},[88],[373,374],[354,376],{"trials":396,"activeCount":98},[],{"trials":398,"activeCount":98},[],{"intervention":400,"totalTrials":130,"cells":401},"IPI1\u002FNIVO3",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":422,"NA":424},{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":98},[],{"trials":409,"activeCount":130,"soonestReadout":213},[410],{"nctId":411,"briefTitle":412,"status":120,"phases":413,"primaryCompletion":213,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":420},"NCT06519266","PHP in Combination With IPI1\u002FNIVO3 Compared to IPI3\u002FNIVO1 Only in Patients With Uveal Melanoma Liver Metastases",[88],"2030-12-31","2024-06-10",40,[418,419],"Uveal Melanoma","Liver Metastases",[400,421],"IPI3\u002FNIVO1",{"trials":423,"activeCount":98},[],{"trials":425,"activeCount":98},[],{"intervention":421,"totalTrials":130,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":440,"NA":442},{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":130,"soonestReadout":213},[436],{"nctId":411,"briefTitle":412,"status":120,"phases":437,"primaryCompletion":213,"completion":414,"start":415,"enrollment":416,"conditions":438,"interventions":439},[88],[418,419],[400,421],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"intervention":445,"totalTrials":130,"cells":446},"Technetium",{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":464,"NA":466},{"trials":448,"activeCount":98},[],{"trials":450,"activeCount":98},[],{"trials":452,"activeCount":98},[],{"trials":454,"activeCount":130,"soonestReadout":368},[455],{"nctId":456,"briefTitle":457,"status":211,"phases":458,"primaryCompletion":368,"completion":368,"start":459,"enrollment":460,"conditions":461,"interventions":463},"NCT07552597","Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II",[88],"2026-05-04",254,[462],"Melanoma (Skin Cancer)",[445],{"trials":465,"activeCount":98},[],{"trials":467,"activeCount":98},[],{"intervention":469,"totalTrials":130,"cells":470},"Standard systemic therapy",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":489,"NA":491},{"trials":472,"activeCount":98},[],{"trials":474,"activeCount":98},[],{"trials":476,"activeCount":98},[],{"trials":478,"activeCount":130,"soonestReadout":483},[479],{"nctId":480,"briefTitle":481,"status":120,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":488},"NCT06141070","Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease",[88],"2028-12-01","2023-12-01",240,[487],"Non Small Cell Lung Cancer",[469],{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":98},[],{"intervention":494,"totalTrials":130,"cells":495},"Temozolomide",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":517,"NA":519},{"trials":497,"activeCount":98},[],{"trials":499,"activeCount":98},[],{"trials":501,"activeCount":98},[],{"trials":503,"activeCount":130,"soonestReadout":508},[504],{"nctId":505,"briefTitle":506,"status":120,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":515},"NCT06419946","Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma",[88],"2031-12-15","2033-12-15","2025-02-01",200,[513,514],"Glioblastoma, IDH-wildtype","MGMT-Methylated Glioblastoma",[494,516],"Lomustine",{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"intervention":516,"totalTrials":130,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":535,"NA":537},{"trials":524,"activeCount":98},[],{"trials":526,"activeCount":98},[],{"trials":528,"activeCount":98},[],{"trials":530,"activeCount":130,"soonestReadout":508},[531],{"nctId":505,"briefTitle":506,"status":120,"phases":532,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":533,"interventions":534},[88],[513,514],[494,516],{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":98},[],{"intervention":540,"totalTrials":94,"cells":541},"Tocilizumab",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":560,"NA":562},{"trials":543,"activeCount":98},[],{"trials":545,"activeCount":98},[],{"trials":547,"activeCount":98},[],{"trials":549,"activeCount":130,"soonestReadout":554},[550],{"nctId":551,"briefTitle":552,"status":120,"phases":553,"primaryCompletion":554,"completion":122,"start":555,"enrollment":556,"conditions":557,"interventions":559},"NCT04561986","TocIlizumab in Late\u002FChronic Active Antibody-mediated Rejection in Kidney Transplant Recipients",[88],"2027-12","2022-02-01",50,[558],"Antibody-mediated Rejection",[540],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[564],{"nctId":565,"briefTitle":566,"status":567,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":573},"NCT03440892","Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients","UNKNOWN",[],"2025-01","2017-11-01",2500,[18],[574,575,576,577,578],"methotrexate","sulfasalazine","abatacept","tocilizumab","tofacitinib\u002Fbaricitinib",{"intervention":39,"totalTrials":94,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":604,"PHASE4":606,"NA":608},{"trials":582,"activeCount":98},[],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":130,"soonestReadout":38},[587,598],{"nctId":588,"briefTitle":589,"status":590,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":556,"conditions":595,"interventions":597},"NCT05359783","Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide","COMPLETED",[86,87],"2023-02-15","2024-04-30","2021-11-01",[15,596],"Sentinel Lymph Node",[39],{"nctId":36,"briefTitle":37,"status":120,"phases":599,"primaryCompletion":38,"completion":600,"start":111,"enrollment":601,"conditions":602,"interventions":603},[87],"2027-07-01",220,[15,596],[39],{"trials":605,"activeCount":98},[],{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":98},[],{"intervention":611,"totalTrials":94,"cells":612},"Pembrolizumab",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":614,"activeCount":98},[],{"trials":616,"activeCount":98},[],{"trials":618,"activeCount":130,"soonestReadout":634},[619,630],{"nctId":620,"briefTitle":621,"status":590,"phases":622,"primaryCompletion":623,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":628},"NCT02697630","Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye",[87],"2023-01-31","2018-02-21",29,[627],"Metastatic Uveal Melanoma",[611,629],"Entinostat",{"nctId":631,"briefTitle":632,"status":120,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT07349303","Neoadjuvant Pembrolizumab in Patients With Stage IIb\u002Fc Melanoma",[87],"2029-05-15","2031-05-15","2026-01-15",30,[462],[611],{"trials":641,"activeCount":98},[],{"trials":643,"activeCount":98},[],{"trials":645,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":662,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":649,"activeCount":98},[],{"trials":651,"activeCount":98},[652],{"nctId":653,"briefTitle":654,"status":590,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":660},"NCT04463368","Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases",[86],"2024-07-26","2021-03-08",18,[418,419],[661,78],"Ipilimumab",{"trials":663,"activeCount":130,"soonestReadout":73},[664],{"nctId":76,"briefTitle":77,"status":120,"phases":665,"primaryCompletion":73,"completion":368,"start":666,"enrollment":667,"conditions":668,"interventions":670},[86,87],"2019-04-01",74,[31,669],"In-Transit Metastasis",[78],{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":98},[],{"intervention":678,"totalTrials":130,"cells":679},"Early start post-transplant vaccination with Gardasil 9®",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":130,"soonestReadout":690},[686],{"nctId":687,"briefTitle":688,"status":120,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":699},"NCT06793410","Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation",[87],"2029-10-31","2025-05-12",100,[694,695,696,697,698],"Recipients of Allogeneic Stem Cell Transplantation","HPV (Human Papillomavirus)-Associated","Acute Myeloid Leukaemia","Myelodysplastic Syndrome","Diffuse Large B Cell Lymphoma (DLBCL)",[678,700],"Late post-transplant vaccination with Gardasil 9®",{"trials":702,"activeCount":98},[],{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"intervention":700,"totalTrials":130,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":719,"PHASE4":721,"NA":723},{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":130,"soonestReadout":690},[715],{"nctId":687,"briefTitle":688,"status":120,"phases":716,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":717,"interventions":718},[87],[694,695,696,697,698],[678,700],{"trials":720,"activeCount":98},[],{"trials":722,"activeCount":98},[],{"trials":724,"activeCount":98},[],{"intervention":64,"totalTrials":130,"cells":726},{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":728,"activeCount":98},[],{"trials":730,"activeCount":98},[],{"trials":732,"activeCount":130,"soonestReadout":63},[733],{"nctId":61,"briefTitle":62,"status":262,"phases":734,"primaryCompletion":63,"completion":735,"start":736,"enrollment":737,"conditions":738,"interventions":740},[87],"2026-06-15","2019-06-01",60,[739],"Cough",[64,741],"Placebos",{"trials":743,"activeCount":98},[],{"trials":745,"activeCount":98},[],{"trials":747,"activeCount":98},[],{"intervention":741,"totalTrials":130,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":751,"activeCount":98},[],{"trials":753,"activeCount":98},[],{"trials":755,"activeCount":130,"soonestReadout":63},[756],{"nctId":61,"briefTitle":62,"status":262,"phases":757,"primaryCompletion":63,"completion":735,"start":736,"enrollment":737,"conditions":758,"interventions":759},[87],[739],[64,741],{"trials":761,"activeCount":98},[],{"trials":763,"activeCount":98},[],{"trials":765,"activeCount":98},[],{"intervention":69,"totalTrials":130,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":769,"activeCount":98},[],{"trials":771,"activeCount":98},[],{"trials":773,"activeCount":130,"soonestReadout":68},[774],{"nctId":66,"briefTitle":67,"status":262,"phases":775,"primaryCompletion":68,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":781},[87],"2027-05","2020-09-03",402,[780],"Neovascular Age-related Macular Degeneration",[69,782],"Aflibercept",{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[],{"intervention":782,"totalTrials":130,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[],{"trials":796,"activeCount":130,"soonestReadout":68},[797],{"nctId":66,"briefTitle":67,"status":262,"phases":798,"primaryCompletion":68,"completion":776,"start":777,"enrollment":778,"conditions":799,"interventions":800},[87],[780],[69,782],{"trials":802,"activeCount":98},[],{"trials":804,"activeCount":98},[],{"trials":806,"activeCount":98},[],{"intervention":44,"totalTrials":808,"cells":809},3,{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":94,"soonestReadout":43},[814,826,831],{"nctId":815,"briefTitle":816,"status":590,"phases":817,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":823},"NCT04812470","Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases",[86],"2025-05-26","2023-02-06",8,[627,822],"Metastatic Cutaneous Melanoma",[44,824,825],"Melphalan","Interleukin-2",{"nctId":41,"briefTitle":42,"status":211,"phases":827,"primaryCompletion":43,"completion":368,"start":828,"enrollment":22,"conditions":829,"interventions":830},[86],"2023-12-31",[418,822],[44,824,825],{"nctId":832,"briefTitle":833,"status":211,"phases":834,"primaryCompletion":835,"completion":836,"start":837,"enrollment":658,"conditions":838,"interventions":839},"NCT07183852","Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma",[86],"2028-03","2033-03","2026-03",[627,822],[44,824,825],{"trials":841,"activeCount":98},[],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"intervention":824,"totalTrials":808,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":94,"soonestReadout":43},[854,858,862],{"nctId":815,"briefTitle":816,"status":590,"phases":855,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":856,"interventions":857},[86],[627,822],[44,824,825],{"nctId":41,"briefTitle":42,"status":211,"phases":859,"primaryCompletion":43,"completion":368,"start":828,"enrollment":22,"conditions":860,"interventions":861},[86],[418,822],[44,824,825],{"nctId":832,"briefTitle":833,"status":211,"phases":863,"primaryCompletion":835,"completion":836,"start":837,"enrollment":658,"conditions":864,"interventions":865},[86],[627,822],[44,824,825],{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":98},[],{"trials":871,"activeCount":98},[],{"trials":873,"activeCount":98},[],{"intervention":825,"totalTrials":808,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":94,"soonestReadout":43},[880,884,888],{"nctId":815,"briefTitle":816,"status":590,"phases":881,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":882,"interventions":883},[86],[627,822],[44,824,825],{"nctId":41,"briefTitle":42,"status":211,"phases":885,"primaryCompletion":43,"completion":368,"start":828,"enrollment":22,"conditions":886,"interventions":887},[86],[418,822],[44,824,825],{"nctId":832,"briefTitle":833,"status":211,"phases":889,"primaryCompletion":835,"completion":836,"start":837,"enrollment":658,"conditions":890,"interventions":891},[86],[627,822],[44,824,825],{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":98},[],{"intervention":54,"totalTrials":130,"cells":901},{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":98},[],{"trials":907,"activeCount":98},[],{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":130,"soonestReadout":53},[914],{"nctId":51,"briefTitle":52,"status":262,"phases":915,"primaryCompletion":53,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":922},[90],"2026-10-30","2016-10-12",249,[920,921],"Lung Transplantation","Allografts",[54,923,924,925,926],"Mycophenolate mofetil","Rabbit Anti thymocyte globulin","Corticosteroids","Tacrolimus",{"intervention":923,"totalTrials":130,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"trials":940,"activeCount":130,"soonestReadout":53},[941],{"nctId":51,"briefTitle":52,"status":262,"phases":942,"primaryCompletion":53,"completion":916,"start":917,"enrollment":918,"conditions":943,"interventions":944},[90],[920,921],[54,923,924,925,926],{"intervention":924,"totalTrials":130,"cells":946},{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":955,"NA":957},{"trials":948,"activeCount":98},[],{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":130,"soonestReadout":53},[959],{"nctId":51,"briefTitle":52,"status":262,"phases":960,"primaryCompletion":53,"completion":916,"start":917,"enrollment":918,"conditions":961,"interventions":962},[90],[920,921],[54,923,924,925,926],{"intervention":925,"totalTrials":130,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":966,"activeCount":98},[],{"trials":968,"activeCount":98},[],{"trials":970,"activeCount":98},[],{"trials":972,"activeCount":98},[],{"trials":974,"activeCount":98},[],{"trials":976,"activeCount":130,"soonestReadout":53},[977],{"nctId":51,"briefTitle":52,"status":262,"phases":978,"primaryCompletion":53,"completion":916,"start":917,"enrollment":918,"conditions":979,"interventions":980},[90],[920,921],[54,923,924,925,926],{"intervention":926,"totalTrials":130,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":991,"NA":993},{"trials":984,"activeCount":98},[],{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":130,"soonestReadout":53},[995],{"nctId":51,"briefTitle":52,"status":262,"phases":996,"primaryCompletion":53,"completion":916,"start":917,"enrollment":918,"conditions":997,"interventions":998},[90],[920,921],[54,923,924,925,926],{"intervention":74,"totalTrials":130,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":130,"soonestReadout":73},[1013],{"nctId":71,"briefTitle":72,"status":120,"phases":1014,"primaryCompletion":73,"completion":73,"start":555,"enrollment":1015,"conditions":1016,"interventions":1018},[90],202,[1017],"Diabetic Foot Ulcer",[74],{"intervention":1020,"totalTrials":130,"cells":1021},"BoNT Injections",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[],{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":130,"soonestReadout":1038},[1034],{"nctId":1035,"briefTitle":1036,"status":120,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":637,"conditions":1041,"interventions":1046},"NCT06733025","Comparing Upper Limb Surgery and Botulinum Toxin for Spasticity: A Paired Design Study",[90],"2029-01-29","2029-06-29","2025-01-07",[1042,1043,1044,1045],"Muscle Spasticity","Spinal Cord Injury","Stroke","Traumatic Brain Injuries",[1020],{"intervention":59,"totalTrials":130,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1050,"activeCount":98},[],{"trials":1052,"activeCount":98},[],{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"trials":1060,"activeCount":130,"soonestReadout":58},[1061],{"nctId":56,"briefTitle":57,"status":211,"phases":1062,"primaryCompletion":58,"completion":554,"start":1063,"enrollment":16,"conditions":1064,"interventions":1068},[90],"2024-09",[1065,1066,1067],"Diabetes Mellitus","Adrenal Insufficiency","Polyglandular Autoimmune Syndrome",[59,1069],"TID Hydrocortisone",{"intervention":1069,"totalTrials":130,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1073,"activeCount":98},[],{"trials":1075,"activeCount":98},[],{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":130,"soonestReadout":58},[1084],{"nctId":56,"briefTitle":57,"status":211,"phases":1085,"primaryCompletion":58,"completion":554,"start":1063,"enrollment":16,"conditions":1086,"interventions":1087},[90],[1065,1066,1067],[59,1069],{"intervention":1089,"totalTrials":130,"cells":1090},"Imatinib 400 MG Oral",{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1092,"activeCount":98},[],{"trials":1094,"activeCount":98},[],{"trials":1096,"activeCount":98},[],{"trials":1098,"activeCount":98},[],{"trials":1100,"activeCount":98},[],{"trials":1102,"activeCount":130,"soonestReadout":1107},[1103],{"nctId":1104,"briefTitle":1105,"status":120,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":416,"conditions":1110,"interventions":1112},"NCT05722795","Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)",[90],"2029-06-28","2029-12-28","2023-06-01",[15,1111],"Triple Negative Breast Cancer",[1089],{"intervention":1114,"totalTrials":130,"cells":1115},"Anti-VEGF treatment",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":130,"soonestReadout":213},[1128],{"nctId":1129,"briefTitle":1130,"status":120,"phases":1131,"primaryCompletion":213,"completion":213,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1141},"NCT06984822","Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant",[90],"2025-08-01",150,[1135,1136,1065,1137,1138,1139,1140],"Diabetic Macular Edema","Visual Impairment","Hyperglycaemia (Diabetic)","Oxidative Stress","Vascular Endothelial Growth Factor","VEGF",[1114],{"intervention":1143,"totalTrials":130,"cells":1144},"Atenativ",{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1153,"NA":1164},{"trials":1146,"activeCount":98},[],{"trials":1148,"activeCount":98},[],{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[1155],{"nctId":1156,"briefTitle":1157,"status":108,"phases":1158,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":98,"conditions":1161,"interventions":1163},"NCT02278575","Atenativ Effect on Uterine Blood Flow and Preeclampsia",[89],"2017-05","2016-01",[1162],"Antithrombin III Deficiency",[1143],{"trials":1165,"activeCount":98},[],{"intervention":1167,"totalTrials":130,"cells":1168},"Prasugrel 10 mg p.o",{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1188},{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[],{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[1179],{"nctId":1180,"briefTitle":1181,"status":590,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":555,"enrollment":1184,"conditions":1185,"interventions":1186},"NCT05183178","Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome",[89],"2025-08-31",17095,[268],[1167,1187],"Ticagrelor 90 mg",{"trials":1189,"activeCount":98},[],{"intervention":1187,"totalTrials":130,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1198,"PHASE4":1200,"NA":1206},{"trials":1193,"activeCount":98},[],{"trials":1195,"activeCount":98},[],{"trials":1197,"activeCount":98},[],{"trials":1199,"activeCount":98},[],{"trials":1201,"activeCount":98},[1202],{"nctId":1180,"briefTitle":1181,"status":590,"phases":1203,"primaryCompletion":1183,"completion":1183,"start":555,"enrollment":1184,"conditions":1204,"interventions":1205},[89],[268],[1167,1187],{"trials":1207,"activeCount":98},[],{"intervention":1209,"totalTrials":130,"cells":1210},"Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1231},{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[],{"trials":1216,"activeCount":98},[],{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":98},[1221],{"nctId":1222,"briefTitle":1223,"status":590,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1230},"NCT02083991","Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation",[89],"2017-01","2017-12","2013-01",224,[1065],[1209],{"trials":1232,"activeCount":98},[],{"intervention":1234,"totalTrials":130,"cells":1235},"Tofacitinib",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1244,"NA":1260},{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[1246],{"nctId":1247,"briefTitle":1248,"status":1249,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":808,"conditions":1254,"interventions":1258},"NCT04311567","Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease","TERMINATED",[89],"2023-11-30","2024-03-26","2020-11-07",[18,1255,1256,1257],"Interstitial Lung Disease Due to Systemic Disease (Disorder)","RA","ILD",[1234,1259],"Methotrexate",{"trials":1261,"activeCount":98},[],{"intervention":1263,"totalTrials":130,"cells":1264},"Progesterone vaginal",{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1273,"NA":1287},{"trials":1266,"activeCount":98},[],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"trials":1272,"activeCount":98},[],{"trials":1274,"activeCount":98},[1275],{"nctId":1276,"briefTitle":1277,"status":567,"phases":1278,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1286},"NCT04725864","Progesterone as Luteal Support in Frozen IVF Natural Cycles",[89],"2025-06-30","2025-12-31","2021-05-01",1800,[1284,1285],"Infertility","Embryo Transfer",[1263],{"trials":1288,"activeCount":98},[],{"intervention":1290,"totalTrials":130,"cells":1291},"alteplase",{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1311,"NA":1313},{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[],{"trials":1297,"activeCount":98},[],{"trials":1299,"activeCount":98},[1300],{"nctId":1301,"briefTitle":1302,"status":567,"phases":1303,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT02894138","Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study",[88],"2021-12","2022-12","2016-09",80,[1309],"ST-segment Elevation Myocardial Infarction",[1290],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"intervention":1316,"totalTrials":130,"cells":1317},"Randomisation course 1 mitoxantrone versus DaunoXome",{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1338,"NA":1340},{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":98},[1326],{"nctId":1327,"briefTitle":1328,"status":567,"phases":1329,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":1333,"conditions":1334,"interventions":1336},"NCT01828489","Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years",[88],"2018-03","2023-03","2013-03",300,[1335],"Pediatric Acute Myeloblastic Leukemia",[1316,1337],"Randomisation course 2 ADxE versus FLADx",{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"intervention":1337,"totalTrials":130,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1356,"NA":1358},{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[1352],{"nctId":1327,"briefTitle":1328,"status":567,"phases":1353,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":1333,"conditions":1354,"interventions":1355},[88],[1335],[1316,1337],{"trials":1357,"activeCount":98},[],{"trials":1359,"activeCount":98},[],{"intervention":1361,"totalTrials":94,"cells":1362},"Ticagrelor 90mg",{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1378,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[1367],{"nctId":1368,"briefTitle":1369,"status":590,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":9,"conditions":1373,"interventions":1375},"NCT03441412","A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor",[86],"2018-03-28","2018-02-28",[1374],"Healthy Volunteers",[1361,1376,1377],"Epinephrine","Metoprolol",{"trials":1379,"activeCount":98},[1380],{"nctId":1381,"briefTitle":1382,"status":590,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":1385,"enrollment":511,"conditions":1386,"interventions":1388},"NCT05149560","Ticagrelor Monotherapy After Stenting",[87],"2025-06-26","2021-12-14",[1387],"Acute Myocardial Infarction",[1361],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"intervention":1396,"totalTrials":130,"cells":1397},"Liraglutide",{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":98},[1404],{"nctId":1405,"briefTitle":1406,"status":590,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":1227,"enrollment":1409,"conditions":1410,"interventions":1412},"NCT02113332","Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections",[87],"2014-08",124,[1411],"Type 2 Diabetes Mellitus",[1396],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"trials":1418,"activeCount":98},[],{"intervention":629,"totalTrials":130,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[1427],{"nctId":620,"briefTitle":621,"status":590,"phases":1428,"primaryCompletion":623,"completion":623,"start":624,"enrollment":625,"conditions":1429,"interventions":1430},[87],[627],[611,629],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[],{"intervention":1438,"totalTrials":130,"cells":1439},"Immunotherapy",{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1441,"activeCount":98},[],{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":98},[1446],{"nctId":1447,"briefTitle":1448,"status":108,"phases":1449,"primaryCompletion":1450,"completion":1451,"start":1452,"enrollment":98,"conditions":1453,"interventions":1457},"NCT04242329","Surgery of Melanoma Metastases After Systemic Therapy",[87],"2023-09-03","2023-09-13","2021-03-11",[31,1454,1455,1456],"Melanoma Stage IV","Metastatic Melanoma","Surgery",[1438],{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"intervention":1465,"totalTrials":130,"cells":1466},"Durvalumab",{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[1473],{"nctId":1474,"briefTitle":1475,"status":590,"phases":1476,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":1480,"interventions":1482},"NCT03446547","Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)",[87],"2025-10-01","2017-12-04",106,[1481],"NSCLC, Stage I",[1465],{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[],{"intervention":1490,"totalTrials":130,"cells":1491},"Varenicline Tartrate 1 mg b.i.d",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1511,"PHASE4":1513,"NA":1515},{"trials":1493,"activeCount":98},[],{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[1498],{"nctId":1499,"briefTitle":1500,"status":590,"phases":1501,"primaryCompletion":1502,"completion":1502,"start":1503,"enrollment":1504,"conditions":1505,"interventions":1509},"NCT04167306","Varenicline and Bupropion for Alcohol Use Disorder",[87],"2022-12-15","2019-03-04",388,[1506,1507,1508],"Alcohol Use Disorder","Alcoholism","Alcohol Dependence",[1490,1510],"Bupropion Hydrochloride 150 mg b.i.d",{"trials":1512,"activeCount":98},[],{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[],{"intervention":1510,"totalTrials":130,"cells":1518},{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1523,"PHASE3":1529,"PHASE4":1531,"NA":1533},{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[1525],{"nctId":1499,"briefTitle":1500,"status":590,"phases":1526,"primaryCompletion":1502,"completion":1502,"start":1503,"enrollment":1504,"conditions":1527,"interventions":1528},[87],[1506,1507,1508],[1490,1510],{"trials":1530,"activeCount":98},[],{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":98},[],{"intervention":1536,"totalTrials":130,"cells":1537},"Cohort 1, Ceplene® and Proleukin®",{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1557,"PHASE4":1559,"NA":1561},{"trials":1539,"activeCount":98},[],{"trials":1541,"activeCount":98},[],{"trials":1543,"activeCount":98},[1544],{"nctId":1545,"briefTitle":1546,"status":567,"phases":1547,"primaryCompletion":1548,"completion":1549,"start":1550,"enrollment":1551,"conditions":1552,"interventions":1554},"NCT03040401","A Study of HDC\u002FIL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)",[86,87],"2018-12-15","2019-12-15","2017-02-15",15,[1553],"Leukemia, Myelomonocytic, Chronic",[1536,1555,1556],"Cohort 2, Ceplene® and Proleukin®","Cohort 3, Ceplene® and Proleukin®",{"trials":1558,"activeCount":98},[],{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":98},[],{"intervention":1555,"totalTrials":130,"cells":1564},{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1575,"PHASE4":1577,"NA":1579},{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[1571],{"nctId":1545,"briefTitle":1546,"status":567,"phases":1572,"primaryCompletion":1548,"completion":1549,"start":1550,"enrollment":1551,"conditions":1573,"interventions":1574},[86,87],[1553],[1536,1555,1556],{"trials":1576,"activeCount":98},[],{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[],{"intervention":1556,"totalTrials":130,"cells":1582},{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1593,"PHASE4":1595,"NA":1597},{"trials":1584,"activeCount":98},[],{"trials":1586,"activeCount":98},[],{"trials":1588,"activeCount":98},[1589],{"nctId":1545,"briefTitle":1546,"status":567,"phases":1590,"primaryCompletion":1548,"completion":1549,"start":1550,"enrollment":1551,"conditions":1591,"interventions":1592},[86,87],[1553],[1536,1555,1556],{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"intervention":1600,"totalTrials":130,"cells":1601},"Arfolitixorin",{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1606,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1603,"activeCount":98},[],{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[1608],{"nctId":1609,"briefTitle":1610,"status":567,"phases":1611,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":637,"conditions":1615,"interventions":1617},"NCT04126655","Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate",[86,87],"2021-10","2021-11","2020-02-05",[1616],"Metastatic Colorectal Cancer",[1600],{"trials":1619,"activeCount":98},[],{"trials":1621,"activeCount":98},[],{"trials":1623,"activeCount":98},[],{"intervention":1625,"totalTrials":130,"cells":1626},"Allopurinol",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1628,"activeCount":98},[],{"trials":1630,"activeCount":98},[],{"trials":1632,"activeCount":98},[1633],{"nctId":1634,"briefTitle":1635,"status":567,"phases":1636,"primaryCompletion":1637,"completion":1638,"start":1225,"enrollment":737,"conditions":1639,"interventions":1641},"NCT03022747","Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol",[87],"2018-12","2019-04",[1640],"Lymphoblastic Leukemia, Acute, Childhood",[1625,1642],"Standard treatment",{"trials":1644,"activeCount":98},[],{"trials":1646,"activeCount":98},[],{"trials":1648,"activeCount":98},[],{"intervention":1642,"totalTrials":130,"cells":1650},{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[],{"trials":1656,"activeCount":98},[1657],{"nctId":1634,"briefTitle":1635,"status":567,"phases":1658,"primaryCompletion":1637,"completion":1638,"start":1225,"enrollment":737,"conditions":1659,"interventions":1660},[87],[1640],[1625,1642],{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"intervention":1668,"totalTrials":130,"cells":1669},"Tadalafil",{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1684,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1671,"activeCount":98},[],{"trials":1673,"activeCount":98},[1674],{"nctId":1675,"briefTitle":1676,"status":1249,"phases":1677,"primaryCompletion":1678,"completion":1678,"start":1679,"enrollment":1680,"conditions":1681,"interventions":1683},"NCT01238224","Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes",[86],"2011-11","2009-11",22,[1682],"Type 2 Diabetes",[1668],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[],{"intervention":661,"totalTrials":130,"cells":1693},{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":98},[1698],{"nctId":653,"briefTitle":654,"status":590,"phases":1699,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":1700,"interventions":1701},[86],[418,419],[661,78],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"intervention":1711,"totalTrials":130,"cells":1712},"Infudopa i.v.",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1730,"PHASE3":1732,"PHASE4":1734,"NA":1736},{"trials":1714,"activeCount":98},[],{"trials":1716,"activeCount":98},[1717],{"nctId":1718,"briefTitle":1719,"status":590,"phases":1720,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1727},"NCT03419806","Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease",[86],"2020-03-27","2020-04-20","2018-02-16",25,[1726],"Parkinson Disease",[1711,1728,1729],"Infudopa s.c.","LCIG",{"trials":1731,"activeCount":98},[],{"trials":1733,"activeCount":98},[],{"trials":1735,"activeCount":98},[],{"trials":1737,"activeCount":98},[],{"intervention":1728,"totalTrials":130,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1748,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[1744],{"nctId":1718,"briefTitle":1719,"status":590,"phases":1745,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":1746,"interventions":1747},[86],[1726],[1711,1728,1729],{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"intervention":1729,"totalTrials":130,"cells":1757},{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1759,"activeCount":98},[],{"trials":1761,"activeCount":98},[1762],{"nctId":1718,"briefTitle":1719,"status":590,"phases":1763,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":1764,"interventions":1765},[86],[1726],[1711,1728,1729],{"trials":1767,"activeCount":98},[],{"trials":1769,"activeCount":98},[],{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[],{"intervention":1376,"totalTrials":130,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1777,"activeCount":98},[],{"trials":1779,"activeCount":98},[1780],{"nctId":1368,"briefTitle":1369,"status":590,"phases":1781,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":9,"conditions":1782,"interventions":1783},[86],[1374],[1361,1376,1377],{"trials":1785,"activeCount":98},[],{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"intervention":1377,"totalTrials":130,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1795,"activeCount":98},[],{"trials":1797,"activeCount":98},[1798],{"nctId":1368,"briefTitle":1369,"status":590,"phases":1799,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":9,"conditions":1800,"interventions":1801},[86],[1374],[1361,1376,1377],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[],{"trials":1809,"activeCount":98},[],{"intervention":1811,"totalTrials":130,"cells":1812},"177Lu-DOTA-TATE + olaparib",{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1829,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[1817],{"nctId":1818,"briefTitle":1819,"status":590,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":658,"conditions":1823,"interventions":1828},"NCT04375267","177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours",[86],"2024-06-30","2020-04-23",[1824,1825,1826,1827],"Clinical Trial, Phase I","Neuroendocrine Tumors","Thymoma","Mesothelioma",[1811],{"trials":1830,"activeCount":98},[],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[],{"intervention":1838,"totalTrials":130,"cells":1839},"211-astatine MX35 F(ab')2",{"EARLY_PHASE1":1840,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1841,"activeCount":98},[1842],{"nctId":1843,"briefTitle":1844,"status":590,"phases":1845,"primaryCompletion":1846,"completion":1847,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1852},"NCT04461457","Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2",[85],"2011-03-19","2012-01-19","2005-02-05",12,[1851],"Ovarian Cancer",[1838],{"trials":1854,"activeCount":98},[],{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":98},[],{"trials":1862,"activeCount":98},[],{"intervention":574,"totalTrials":94,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1871,"PHASE4":1873,"NA":1879},{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[],{"trials":1874,"activeCount":98},[1875],{"nctId":1247,"briefTitle":1248,"status":1249,"phases":1876,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":808,"conditions":1877,"interventions":1878},[89],[18,1255,1256,1257],[1234,1259],{"trials":1880,"activeCount":98},[1881],{"nctId":565,"briefTitle":566,"status":567,"phases":1882,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":1883,"interventions":1884},[],[18],[574,575,576,577,578],{"intervention":1886,"totalTrials":130,"cells":1887},"BF200-ALA\u002F5-aminolevulinic acid",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1894,"PHASE4":1896,"NA":1898},{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[],{"trials":1895,"activeCount":98},[],{"trials":1897,"activeCount":98},[],{"trials":1899,"activeCount":98},[1900],{"nctId":1901,"briefTitle":1902,"status":590,"phases":1903,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":637,"conditions":1906,"interventions":1910},"NCT02644187","Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol",[90],"2017-03","2015-12",[1907,1908,1909],"Therapy, Photodynamic","Keratosis, Actinic","Pain",[1886],{"intervention":1912,"totalTrials":130,"cells":1913},"Generic tacrolimus",{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[],{"trials":1925,"activeCount":98},[1926],{"nctId":1927,"briefTitle":1928,"status":590,"phases":1929,"primaryCompletion":1306,"completion":1930,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1935},"NCT02587052","A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac",[],"2016-12","2015-10",186,[1934],"Renal Transplantation",[1912,1936],"Prograf",{"intervention":1936,"totalTrials":130,"cells":1938},{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1945,"PHASE4":1947,"NA":1949},{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[],{"trials":1946,"activeCount":98},[],{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[1951],{"nctId":1927,"briefTitle":1928,"status":590,"phases":1952,"primaryCompletion":1306,"completion":1930,"start":1931,"enrollment":1932,"conditions":1953,"interventions":1954},[],[1934],[1912,1936],{"intervention":1956,"totalTrials":130,"cells":1957},"Capecitabine, Cyclophosphamide",{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1959,"activeCount":98},[],{"trials":1961,"activeCount":98},[],{"trials":1963,"activeCount":98},[],{"trials":1965,"activeCount":98},[],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[1970],{"nctId":1971,"briefTitle":1972,"status":590,"phases":1973,"primaryCompletion":1974,"completion":1974,"start":1975,"enrollment":416,"conditions":1976,"interventions":1979},"NCT04350021","Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer",[],"2023-10-30","2019-03-01",[1977,1978],"Breast Cancer Metastatic","Chemotherapy Effect",[1956],{"intervention":1981,"totalTrials":130,"cells":1982},"Leucovorin",{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":1991,"NA":1993},{"trials":1984,"activeCount":98},[],{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":98},[1995],{"nctId":1996,"briefTitle":1997,"status":567,"phases":1998,"primaryCompletion":1999,"completion":2000,"start":1306,"enrollment":2001,"conditions":2002,"interventions":2005},"NCT02959541","PK\u002FPD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer",[90],"2020-05-26","2022-12-31",48,[2003,2004],"Colon Cancer","Chemotherapy",[1981],{"intervention":2007,"totalTrials":130,"cells":2008},"TNF-α inhibitor OR JAK inhibitor",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2019},{"trials":2010,"activeCount":98},[],{"trials":2012,"activeCount":98},[],{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[],{"trials":2020,"activeCount":98},[2021],{"nctId":2022,"briefTitle":2023,"status":567,"phases":2024,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2033},"NCT04378621","Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients",[90],"2025-09-01","2020-10-01",212,[18,1909,2029,2030,24,2031,2032],"Fatigue","Cognitive Decline","Brain Diseases","Hand Rheumatism",[2007],{"intervention":575,"totalTrials":130,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2037,"activeCount":98},[],{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[2048],{"nctId":565,"briefTitle":566,"status":567,"phases":2049,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":2050,"interventions":2051},[],[18],[574,575,576,577,578],{"intervention":576,"totalTrials":130,"cells":2053},{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2060,"PHASE4":2062,"NA":2064},{"trials":2055,"activeCount":98},[],{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[],{"trials":2063,"activeCount":98},[],{"trials":2065,"activeCount":98},[2066],{"nctId":565,"briefTitle":566,"status":567,"phases":2067,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":2068,"interventions":2069},[],[18],[574,575,576,577,578],{"intervention":578,"totalTrials":130,"cells":2071},{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2078,"PHASE4":2080,"NA":2082},{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"trials":2079,"activeCount":98},[],{"trials":2081,"activeCount":98},[],{"trials":2083,"activeCount":98},[2084],{"nctId":565,"briefTitle":566,"status":567,"phases":2085,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":2086,"interventions":2087},[],[18],[574,575,576,577,578],{"intervention":2089,"totalTrials":130,"cells":2090},"Crystalloid based prime solution",{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":98},[],{"trials":2098,"activeCount":98},[],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[2103],{"nctId":2104,"briefTitle":2105,"status":590,"phases":2106,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":658,"conditions":2110,"interventions":2112},"NCT03073304","A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion.",[90],"2018-02-20","2018-04-20","2017-02-24",[31,2111],"Sarcoma",[2089,2113],"Erythrocyte based prime solution",{"intervention":2113,"totalTrials":130,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[2128],{"nctId":2104,"briefTitle":2105,"status":590,"phases":2129,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":658,"conditions":2130,"interventions":2131},[90],[31,2111],[2089,2113],{"intervention":2133,"totalTrials":130,"cells":2134},"Infliximab",{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2136,"activeCount":98},[],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[2147],{"nctId":2148,"briefTitle":2149,"status":590,"phases":2150,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":2153,"conditions":2154,"interventions":2157},"NCT06269185","Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis",[],"2024-10-18","2024-03-06",271,[2155,2156],"Ulcerative Colitis","Inflammatory Bowel Diseases",[2133,2158],"Adalimumab",{"intervention":2158,"totalTrials":130,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2162,"activeCount":98},[],{"trials":2164,"activeCount":98},[],{"trials":2166,"activeCount":98},[],{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[2173],{"nctId":2148,"briefTitle":2149,"status":590,"phases":2174,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":2153,"conditions":2175,"interventions":2176},[],[2155,2156],[2133,2158],{"intervention":2178,"totalTrials":130,"cells":2179},"MagTrace only",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[2192],{"nctId":2193,"briefTitle":2194,"status":590,"phases":2195,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":1307,"conditions":2199,"interventions":2200},"NCT05625698","Premarking of Axillary Nodes Before Start of Neoadjuvant Chemotherapy Using Magnetic Approach",[90],"2023-10-28","2023-11-28","2021-10-01",[15],[2178,2201],"MagTrace and Magseed",{"intervention":2201,"totalTrials":130,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"trials":2211,"activeCount":98},[],{"trials":2213,"activeCount":98},[],{"trials":2215,"activeCount":98},[2216],{"nctId":2193,"briefTitle":2194,"status":590,"phases":2217,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":1307,"conditions":2218,"interventions":2219},[90],[15],[2178,2201],{"intervention":2221,"totalTrials":130,"cells":2222},"Blood sample",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[2235],{"nctId":2236,"briefTitle":2237,"status":590,"phases":2238,"primaryCompletion":2239,"completion":2239,"start":2240,"enrollment":2241,"conditions":2242,"interventions":2245},"NCT04206163","Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis",[90],"2024-06-24","2020-01-20",78,[2243,2244],"Acute Myocarditis","Cardiac Sarcoidosis",[2221],{"intervention":2247,"totalTrials":130,"cells":2248},"Hydrocortisone",{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[2261],{"nctId":2262,"briefTitle":2263,"status":590,"phases":2264,"primaryCompletion":1930,"completion":1930,"start":2265,"enrollment":2266,"conditions":2267,"interventions":2269},"NCT02152553","Biomarker(s) for Glucocorticoids",[90],"2014-05",11,[2268],"Addison Disease",[2247],{"intervention":2271,"totalTrials":130,"cells":2272},"Salbutamol (as Salbutamol Sulfate) 2 Mg Oral",{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[],{"trials":2282,"activeCount":98},[],{"trials":2284,"activeCount":98},[2285],{"nctId":2286,"briefTitle":2287,"status":590,"phases":2288,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":658,"conditions":2291,"interventions":2298},"NCT05099107","Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment",[90],"2025-03-17","2021-10-25",[2292,2293,2294,2295,2296,2297],"Congenital Myopathy","Neuromuscular Diseases","Musculoskeletal Diseases","Nemaline Myopathy","Centronuclear Myopathy","Myosin Storage Myopathy",[2271,2299],"Salbutamol Only Product in Oral Dose Form",{"intervention":2299,"totalTrials":130,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2303,"activeCount":98},[],{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[2314],{"nctId":2286,"briefTitle":2287,"status":590,"phases":2315,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":658,"conditions":2316,"interventions":2317},[90],[2292,2293,2294,2295,2296,2297],[2271,2299]]